Evommune EVMN
NYSE EVMN
$6.88 -0.31 (-4.31%)
At close: Oct 2, 2026 · 4:00 PM EDT

Evommune (EVMN) Return on Assets [ROA] (2025 - 2026)

Updated

Evommune (EVMN) reported Return on Assets [ROA] of -30.32% for Q2 2026, up 0.74 percentage points from the prior quarter.

Analysis

Evommune (EVMN) Return on Assets [ROA] (2025 - 2026) Analysis & Trends

For FY2025, Evommune posted Return on Assets [ROA] of -51.66%.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROA (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn 20.64%
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn 10.47%
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn 4.65%
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn 2.45%
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn 28.37%
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn 9.10%
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn 9.29%
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn -6.13%
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn 2.14%
10 Evommune 249.62 Mn -387.90 Mn - -30.32%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -30.32%
Mar 31, 2026 -31.06%
Dec 31, 2025 -50.24%
API Access

Evommune Return on Assets [ROA] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-assets-%5Broa%5D&ticker=EVMN&period=max&api_key=YOUR_API_KEY